This 2-module continuing pharmacy education—(CPE) Strategy Session brings together 2 expert pharmacists to discuss treatment goals and value-based care for patients with newly diagnosed multiple myeloma. Learners must complete both modules to receive credit.

In Module 1 of this CPE-approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.

In Module 2 of this CPE-approved activity, Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.

Start the activity now!

This case-based discussion brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Start the activity now.

Presented by Dr. Shawn Kwatra, Director, John Hopkins Itch Center, Associate Professor of Dermatology, John Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.

In this session, Constance Visovsky, PhD, RN, ACNP, FAAN, Director and the Lewis & Leona Hughes Endowed Chair of the College of Nursing at the University of South Florida, will clarify the mechanism by which CDK4/6 inhibitors in combination with endocrine therapy are thought to overcome resistance to endocrine therapy in ER-positive metastatic breast cancer, including the data that led to the approval of abemaciclib in the early-stage breast cancer setting, as well as early and aggressive identification of side effects to minimize toxicity.

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, will explore the uses of immune checkpoint inhibition, a therapeutic strategy which is moving to earlier settings in breast cancer, including preoperative therapy with pembrolizumab/chemotherapy. The discussion will include an overview of immune-mediated adverse events and how they can be graded and managed. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explain the benefit of PARP inhibitors for breast cancer in patients with germline BRCA mutations and will present the latest data justifying the recent approval of olaparib for adjuvant therapy in high-risk early breast cancer. She will also highlight the side effect profiles of PARP inhibitors and the importance of counseling patients about the side effects they may experience. Start the activity now!

In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explore the role of PI3K inhibitors for patients with a mutation in PIK3CA nd HR-positive, HER2-negative breast cancer, including alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents. Start the activity now!

In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review the current options for treatment of HER2-positive breast cancer using HER2-targeted monoclonal antibodies, including the advantages and disadvantages regarding the combination of trastuzumab/pertuzumab/hyaluronidase, the indications for margetuximab, and the latest guidance on managing cardiac and other adverse events with HER2-targeted monoclonal antibody therapy. Start the activity now!

In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. She will also highlight the differing considerations for management of patients taking these drugs. Start the activity now!